AGÕæÈ˹ٷ½

STOCK TITAN

GRAIL to Present at Canaccord Genuity 45th Annual Growth Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

GRAIL (Nasdaq: GRAL), a healthcare company focused on early cancer detection, has announced its participation in the Canaccord Genuity 45th Annual Growth Conference. The presentation is scheduled for Wednesday, August 13 at 8:30 a.m. ET in Boston.

Investors can access both live and replay webcasts through GRAIL's investor relations website at investors.grail.com. The webcast recording will remain available for a minimum of 30 days following the event.

GRAIL (Nasdaq: GRAL), un'azienda sanitaria specializzata nella diagnosi precoce del cancro, ha annunciato la sua partecipazione alla 45ª Conferenza Annuale sulla Crescita di Canaccord Genuity. La presentazione è prevista per mercoledì 13 agosto alle 8:30 ET a Boston.

Gli investitori potranno accedere alle trasmissioni in diretta e alle repliche tramite il sito web delle relazioni con gli investitori di GRAIL all'indirizzo investors.grail.com. La registrazione del webcast sarà disponibile per almeno 30 giorni dopo l'evento.

GRAIL (Nasdaq: GRAL), una empresa de salud centrada en la detección temprana del cáncer, ha anunciado su participación en la 45ª Conferencia Anual de Crecimiento de Canaccord Genuity. La presentación está programada para el miércoles 13 de agosto a las 8:30 a.m. ET en Boston.

Los inversores pueden acceder a las transmisiones en vivo y a las repeticiones a través del sitio web de relaciones con inversores de GRAIL en investors.grail.com. La grabación del webcast estará disponible por un mínimo de 30 días después del evento.

GRAIL (나스ë‹�: GRAL)ì€ ì¡°ê¸° ì•� 진단ì—� 중ì ì� ë‘� ì˜ë£Œ 회사ë¡�, Canaccord Genuity ì �45íš� ì—°ë¡€ 성장 컨í¼ëŸ°ìФì—� 참여í•� 것ì´ë¼ê³  발표했습니다. 발표ëŠ� 8ì›� 13ì� 수요ì� 오전 8ì‹� 30ë¶�(ë™ë¶€ì‹œê°„)ì—� 보스턴ì—ì„� 예정ë˜ì–´ 있습니다.

투ìžìžë“¤ì€ GRAILì� 투ìžìž� ê´€ê³� 웹사ì´íЏ investors.grail.comì� 통해 ìƒì¤‘ê³� ë°� 다시보기 웹ìºìŠ¤íŠ¸ì—� ì ‘ì†í•� ìˆ� 있습니다. 웹ìºìŠ¤íŠ¸ 녹화ëŠ� 행사 í›� 최소 30ì¼ê°„ 제공ë©ë‹ˆë‹�.

GRAIL (Nasdaq : GRAL), une entreprise de santé spécialisée dans la détection précoce du cancer, a annoncé sa participation à la 45e conférence annuelle sur la croissance de Canaccord Genuity. La présentation est prévue pour le mercredi 13 août à 8h30 ET à Boston.

Les investisseurs peuvent accéder aux webdiffusions en direct et en replay via le site des relations investisseurs de GRAIL à l'adresse investors.grail.com. L'enregistrement du webcast restera disponible pendant au moins 30 jours après l'événement.

GRAIL (Nasdaq: GRAL), ein Gesundheitsunternehmen mit Fokus auf die frühzeitige Krebsdiagnose, hat seine Teilnahme an der 45. jährlichen Wachstums-Konferenz von Canaccord Genuity angekündigt. Die Präsentation ist für Mittwoch, den 13. August um 8:30 Uhr ET in Boston geplant.

Investoren können sowohl Live- als auch Wiederholungs-Webcasts über die Investor-Relations-Website von GRAIL unter investors.grail.com abrufen. Die Aufzeichnung des Webcasts wird mindestens 30 Tage nach der Veranstaltung verfügbar sein.

Positive
  • None.
Negative
  • None.

MENLO PARK, Calif., July 30, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Canaccord Genuity 45th Annual Growth Conference in Boston on Wednesday, Aug. 13 at 8:30 a.m. ET. 

Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at . The webcast will be archived and available for reply for at least 30 days after the event.

About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom.
For more information, visit .

Cision View original content to download multimedia:

SOURCE GRAIL, Inc.

FAQ

When is GRAIL (GRAL) presenting at the Canaccord Genuity Growth Conference?

GRAIL will present at the conference on Wednesday, August 13, 2025, at 8:30 a.m. ET in Boston.

How can investors access GRAIL's Canaccord conference presentation?

Investors can access both the live and replay webcasts through GRAIL's investor relations website at investors.grail.com.

How long will GRAIL's Canaccord conference presentation be available for replay?

The webcast will be archived and available for replay for at least 30 days after the event.

What is GRAIL's (GRAL) main business focus?

GRAIL is a healthcare company focused on early cancer detection with the mission of detecting cancer early when it can be cured.
Grail Inc

NASDAQ:GRAL

GRAL Rankings

GRAL Latest News

GRAL Latest SEC Filings

GRAL Stock Data

1.38B
30.99M
13.64%
78.95%
10.74%
Diagnostics & Research
Services-medical Laboratories
United States
MENLO PARK